

Shaping the Future of Myeloma Treatment



Sergio A. Giralt, MD

Chief Attending, BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. In addition to his positions at Memorial Sloan Kettering Cancer Center, Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Melvin Berlin Family Chair in Myeloma Research.

Dr. Giralt is an active member of several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology, the North American Society of Blood and Bone Marrow Transplantation (ASBMT), the International Society of Hematotherapy and Graft Engineering, and the Gerontological Society of America. He previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research and the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and he is past president of ASBMT.

A board-certified hematologist/oncologist whose clinical practice and research focus on stem cell transplantation for patients with blood disorders, Dr. Giralt with his colleagues pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. Currently, Dr. Giralt's research is examining the use of T-cell depletion techniques to dramatically reduce the risk of graft-versus-host disease. He has published and presented extensively on these topics. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.